Fate Therapeutics (FATE) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Cowen Sees High Probability of Positive Data ASH at from Fate Therapeutics (FATE)
November 4, 2015 7:12 AM ESTCowen analyst Boris Peaker reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) and sees high probability of positive data at ASH.
Peaker commented, "Fate provided a pipeline update on its 3Q15 call as well as an overview of its... More
